You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Demand Driven Healthcare Scheduling using Flexible Shifts and Monte-Carlo Simulat

    SBC: Acme Express, Inc.            Topic: NINR

    DESCRIPTION (provided by applicant): The shortage of nurses and medical technologists is accelerating. Shortages can be reduced by scheduling staff to precisely meet the hour-by-hour demand for medical service. Think of bank teller scheduling, where more staff are scheduled at peak demand. Current attempts to schedule to demand are relatively primitive: a small number of quantized fixed shifts, fo ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Refinement of lead compounds to modulate water permeability through AQP4

    SBC: AEROMICS, Inc.            Topic: NINDS

    DESCRIPTION (provided by applicant): Cerebral edema (and its counterpart in the spinal cord) is a major contributor to the damage caused by stroke, traumatic brain injury, traumatic spinal-cord injury, and bacterial meningitis. Stroke alone is the third leading cause of death in the USA and the leading cause of disability. Unfortunately, few treatment options are available for cerebral and spinal- ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Therapeutic Potential of Ex vivo expanded Human Cord Blood derived CD133+ cells i

    SBC: Arteriocyte, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Critical Limb Ischemia (CLI) is a common problem that often results in major limb amputation. Circulating endothelial progenitor cells likely play a role in the pathogenesis of CLI; the number and function of these cells that are mobilized from the bone marrow are reduced in the elderly and diabetics, groups at high risk for CLI. Allogenic Umbilical Cord Blood ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  4. A Novel Expansion of Primary Leukemia Stem Cells

    SBC: Arteriocyte, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Arteriocyte's long-term objective is to develop a platform for ex vivo expansion of leukemic stem cell (LSC) based on cytokine-enriched medium and the company's proprietary nanofiber culture scaffold (NANEX). Cancer stem cell research is of significant importance because, this approach has the potential to create an effective therapy that overcomes challenges o ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Halogenated Insulin: a fast-acting, ultra stable analog.

    SBC: THERMALIN DIABETES, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): A Phase 1 SBIR program of pre-clinical development is proposed focusing on a novel rapid-acting insulin analog for the treatment of diabetes mellitus. Designated Insulin-Cl, our product is a derivative of insulin lispro (the active component of HumalogTM) containing a single chloro-substitution within the aromatic ring of a conserved phenylalanine in the B-chai ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel 'Zinc-Stapled' Long-Acting Insulin Analog

    SBC: THERMALIN DIABETES, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): A Phase 1 SBIR program of pre-clinical development is proposed focusing on a novel long-acting insulin analog for the basal treatment of diabetes mellitus. Designated Insulin-ZN, our product is a derivative of human insulin containing novel zinc-binding sites at the periphery of the insulin hexamer. The non-classical zinc-binding sites are mediated by paired (i ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Optimization of the angiogenic potential of multipotent adult progenitor cells

    SBC: ATHERSYS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Peripheral Vascular Disease (PVD) results from chronic loss of the oxygen supply to the lower limbs due to arterial blockage. Loss of oxygen to these tissues can result in pain, ulcers, infection and limb amputation in patients. PVD affects up to 12% of the population globally with increased risk in patients with diabetes, hypertension, advanced age and obesity ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. SapC-DOPS nanovesicles for Treating Glioblastoma Multiforme

    SBC: BEXION PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Our goal is to develop a new molecular entity with a novel mechanism of action for targeting and eliminating glioblastoma multiforme (GBM, high grade glioma), a deadly and invasive brain tumor with no effective treatment. Of the 12,000 patients expected to be diagnosed with GBM this year, most will succumb within the first year. Clearly, there is an urgent ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Development of Multivalent Vaccines Against Yellow Fever and Arena Viruses

    SBC: BIOPROTECTION SYSTEMS CORP.            Topic: NIAID

    DESCRIPTION (provided by applicant): Indigenous population, travelers and troops present in Africa and South America are clearly at risk of exposure to several arenaviruses. Several human pathogenic arenaviruses, e.g., Lassa and Junin viruses, are listed on the NIAID's Priority Pathogens and CDC's Bioterrorism Agents Lists and can cause a deadly hemorrhagic fever. No effective and safe vaccine is ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Optimizing the Action Potential of Stem Cell-derived Human Cardiomyocytes for Car

    SBC: CHANTEST, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Stem Cell-derived Human Cardiomyocytes (SC-hCMs) offer great potential for improving the accuracy of pre-clinical cardiac safety screening. We have recently characterized a population of SC-hCMs that will be made commercially available in 2010 by our collaborator GE Healthcare, and have demonstrated that these cells show sensitive pharmacology that accurately p ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government